Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Axsome TherapeuticsMIL:1AXSM -1.81%33 Days Inventory is 233.05 as of Jun. 2026, which is 38% above its 10-year median of 168.51. GuruFocus rates MIL:1AXSM with a GF Score™ of 33/100 and a GF Value™ of €187.73 (Fairly Valued). The stock has 1 warning sign investors should review. Among 637 Biotechnology companies, Axsome Therapeutics ranks worse than 53.69% on this metric.
The historical rank and industry rank for Axsome Therapeutics's Days Inventory or its related term are showing as below:
MIL:1AXSM'
s Days Inventory Range Over the Past 10 Years
Min: 136.22 Med: 168.51 Max: 303.35
Current: 193.93
During the past 13 years, Axsome Therapeutics's highest Days Inventory was 303.35. The lowest was 136.22. And the median was 168.51.
MIL:1AXSM's Days Inventory is ranked worse than 53.69% of 637
companies
in the Biotechnology industry
Industry Median: 180.38
vs MIL:1AXSM: 193.93
Axsome Therapeutics's Days Inventory
increased
from Jun. 2025 (121.64) to Jun. 2026 (233.05).
It might indicate that Axsome Therapeutics's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Axsome Therapeutics's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.39.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Axsome Therapeutics's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.16.
Axsome Therapeutics (MIL:1AXSM) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Axsome Therapeutics's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Axsome Therapeutics's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Axsome Therapeutics Days Inventory Related Terms
Axsome Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Axsome Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1AXSM vs MDGL, ARWR, BMRN: Days Inventory Comparison
For the Biotechnology subindustry, Axsome Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Axsome Therapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Axsome Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axsome Therapeutics (MIL:1AXSM) has a Days Inventory of 233.05 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Axsome Therapeutics and its competitors. This is 38% above median its historical median of 168.51. Over the past decade, Axsome Therapeutics' Days Inventory has ranged from 136.22 to 303.35. According to the industry distribution chart, Axsome Therapeutics ranks #342 out of 637 companies in the Biotechnology industry, placing it in the top 53.7%.
Is Axsome Therapeutics' Days Inventory too high?
Axsome Therapeutics' current Days Inventory of 233.05 is 38% above median its 10-year median of 168.51. Over the past 10 years, this metric has ranged from a low of 136.22 to a high of 303.35. The Biotechnology industry median Days Inventory is 180.38. Axsome Therapeutics' value of 233.05 is 29.2% above this industry median. Based on the distribution chart, Axsome Therapeutics ranks #342 out of 637 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Axsome Therapeutics has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Days Inventory compare to MDGL and ARWR?
According to the Biotechnology industry distribution chart, Axsome Therapeutics ranks #342 out of 637 companies for Days Inventory. This places Axsome Therapeutics in the lower half of its industry. The industry median Days Inventory is 180.38. Axsome Therapeutics' value of 233.05 is 29.2% above this benchmark. Historically, Axsome Therapeutics' own Days Inventory has ranged from 136.22 to 303.35 over the past decade. While the company's 10-year median is 168.51 vs. the industry median of 180.38, Axsome Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 180.38, based on 637 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Axsome Therapeutics's current Days Inventory of 233.05 is 29.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Axsome Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 180.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Axsome Therapeutics's current Days Inventory is 233.05, which is 38% above median its own 10-year median of 168.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (MIL:1AXSM) is currently considered Fairly Valued. The stock's GF Value™ is €187.73, compared to a current price of €184.75 — trading 1.6% below its estimated fair value. The current Days Inventory is 233.05, which is 38% above median its 10-year median of 168.51 and 29.2% above the Biotechnology industry median of 180.38. Axsome Therapeutics' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Axsome Therapeutics (MIL:1AXSM), the current Days Inventory is 233.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Axsome Therapeutics (MIL:1AXSM) Overvalued in 2026?
Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be undervalued.
The current stock price of €184.75 is trading 1.6% below its estimated GF Value™ of €187.73.
GuruFocus considers Axsome Therapeutics to be Fairly Valued.
Key valuation signals for MIL:1AXSM:
Days Inventory: 233.05 (38% above median its 10-year median of 168.51)
GF Value™: €187.73 vs. price of €184.75 (1.6% below fair value)
Industry Position: 29.2% above the Biotechnology median (#342 of 637)
No single metric tells the full story. See the MIL:1AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
33GF Score
Get the complete analysis for MIL:1AXSM
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1AXSM has been successfully added to your 
